The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Eli Lilly

Monday Biotech Deal Review: April 12, 2010

This week deals are back in full force, despite the fact that Tengion’s IPO was less popular than expected and Neovacs scaled back its planned IPO.  Highlights include Patheon raising $280 million from its note placement, Verio Therapeutics getting phagocytosed by Fate (but remaining in Ottawa) and Lorus Therapeutics’ F-1 filing for a $17.5 million unit offering. Read more of this post

Biotech Trends Update: Jubilant’s R&D Success Continues Drive Toward Innovation in Asia

world_map_2002One of the biotech trends we’re following in 2010 is the increasing innovative activity in India and China.  Both are booming not only as low cost manufacturing centers but also as innovative hubs adding R&D expertise and specialized know-how.

This week, the Indian company Jubilant and Endo Pharmaceuticals announced that they are expanding thier partnership following early and rapid success by Jubliant’s team.  Jubilant has been developing pre-clinical candidates for Endo’s oncology pipeline.  As Endo’s R&D VP says, they are executing on a “strategy of building Endo’s pipeline using a virtual discovery approach” as a complement to their in-licensing strategy.

Jubilant has been running with these types of “virtual discovery” deals, including its collaboration with AstraZeneca that we noted at the time (even as AZ is shedding in-house capacity today), a successful partnership with Lilly and tie-ups with academic institutions including Duke University and UAB.

FierceBiotech reports that Biocon’s Kiran Mazumdar-Shaw predicts a $5 billion Indian biotech business in 2011 that will “double to $10 billion by 2015″ based on “opportunities in clinical trials, manufacturing and more.” 

The greater the contribution R&D makes to India’s growth, the better positioned the country (and the region) will be in the coming years to lead the global industry forward.

Bookmark and Share

BioMS and Lilly Terminate Dirucotide Agreement

Not surprising, given the failure of the SPMS trial (etc.) in July, but Eli Lilly and BioMS have terminated their license and collaboration agreement, with “all commercial rights to dirucotide … returned to BioMS.”  No indication from the press release where BioMS is headed, just that they’re “completing [their] review of the additional dirucotide clinical data and assessing the strategic options available.”  Sigh.

Bookmark and Share

Monday Deal Review: August 24, 2009

Takeda Canada’s Opening Move: Reacquire Rights to Diabetes Drug ACTOS from Eli Lilly Canada

Takeda Canada, which opened in Mississauga in March, bought back the commercial rights to pioglitazone HCl, a type 2 diabetes drug marketed as ACTOS, from Eli Lilly Canada. Financial terms were not disclosed. Lilly had been marketing the drug in Canada under a 1999 worldwide agreement with Takeda.

Takeda Canada general manager Daaron Dohler characterized the move as “Takeda’s first opportunity to establish a commercial presence in Canada.” The company has job postings up for a manager of sales and marketing operations and two marketing directors.

Having said in March that they were targeting an NDS submission for the end of 2009, I wonder if this move points toward another diabetes product… Stay tuned.

Update: FierceBiotech’s post on the transaction this morning also notes the “boost” ACTOS got last week from the results of a comparative study against GSK’s Avandia.

Bookmark and Share

Monday Deal Review: August 10, 2009

B&W_BigNickelConsidering last week was abbreviated for the August long weekend here in Canada, there’s a decent amount of activity to run through.  Check out this week’s deals after the jump…

Trends Update — Comparative Effectiveness and Personalized Medicine: Genetic Test Identifies Patient Subpopulation for Benefit, Avoids Wasted Money and Time for Others on Erbitux, Vectibix

B&W_DNA_sequenceThis is exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and payors:

  • data shows that patients with KRAS mutations don’t benefit from anti-EGFR antibody meds Erbitux or Vectibix;
  • the FDA approves a labeling change identifying the patients who won’t benefit;
  • payors see costs savings from eliminating pointless prescriptions;
  • patients without the KRAS mutations have added incentive to take the drugs, benefiting themselves and the pharma companies who make the drugs.

As the WSJ Health Blog says:

“Erbitux and other expensive cancer medicines have faced repeated questions about whether drugs that prolong life for short periods of time are worth the high costs… Not using Erbitux as a first-line treatment for [KRAS-variant] patients could save about $600 million a year.”

The manufacturers Bloomberg’s reporter spoke to are fully supportive:

“‘The inclusion of KRAS as a biomarker in the Erbitux labeling helps physicians to better understand the most appropriate use of the drug in the management of patients with metastatic colorectal cancer,’ said Fouad Namouni, an oncology executive for Bristol-Myers …

Physicians can eliminate Vectibix and Erbitux for colon cancer patients with the KRAS mutation and ‘redirect those patients to alternative therapies, avoiding unnecessary treatments in patients who are unlikely to benefit,’ said Sean Harper, Amgen’s chief medical officer.”

Share Button

Trends Update — Shifting IP Constituencies: AstraZeneca’s R&D Investment in India’s Jubilant

world_map_2002One of our trends in 2009 series is following the increasing innovative activity in India and China, which has the potential to reshape WTO debates around IP protection.

Yesterday, FierceBiotech picked up a Reuters report that AstraZeneca will be funding five years’ work in neuroscience R&D at India’s Jubilant Organosys.  Jubilant was… well … very happy about the deal, which could lead to up to $200 million in milestone payments.  Jubilant also works with Eli Lilly on drug discovery and partnered drug development.  Interestingly, the article juxtaposes Jubilant’s R&D deal with its Monday FDA approval for a generic product.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 131 other followers